The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.
 
Yu Sunakawa
Honoraria - Takeda
 
Sebastian Stintzing
Honoraria - Amgen; Merck KGaA; Roche/Genentech; Sanofi; Sirtex Medical
Consulting or Advisory Role - Amgen; Merck KGaA; Roche/Genentech
Travel, Accommodations, Expenses - Merck KGaA; Roche/Genentech
 
Volker Heinemann
Honoraria - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Roche; Sanofi
Research Funding - Amgen; Merck Serono; Pfizer; Roche
 
Fotios Loupakis
Consulting or Advisory Role - Amgen; Sanofi
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi
Research Funding - Merck Serono; Roche
 
Chiara Cremolini
Consulting or Advisory Role - Bayer; Roche
Speakers' Bureau - Bayer
 
Shu Cao
No Relationships to Disclose
 
Dongyun Yang
No Relationships to Disclose
 
Wu Zhang
No Relationships to Disclose
 
Anish Parekh
No Relationships to Disclose
 
Shinichi Yamauchi
No Relationships to Disclose
 
Yan Ning
No Relationships to Disclose
 
Stefan Stremitzer
No Relationships to Disclose
 
Satoshi Matsusaka
No Relationships to Disclose
 
Angela Mendez
No Relationships to Disclose
 
Rita Elie El-Khoueiry
No Relationships to Disclose
 
Heinz-Josef Lenz
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Merck KGaA; Vela Diagnostics
Research Funding - Bristol-Myers Squibb; Genentech; Merck KGaA; Novartis